Dupixent does it again as Sanofi raises guidance

Sanofi (Euronext: SAN) has upped its full-year 2022 guidance in presenting the group’s second-quarter financial results.

The French drugmaker was once again indebted to its allergic diseases drug Dupixent (dupilumab) for delivering results that exceeded estimates.

"We delivered important pipeline milestones such as the approval of Dupixent in its fourth disease indication, eosinophilic esophagitis"Sanofi's second-quarter business operating income, or adjusted earnings before interest and tax, jumped from the same quarter last year by 22% to 2.75 billion euros ($2.81 billion).